{"id":"hbm9036-0-25-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HBM9036 selectively blocks the C5a complement receptor (C5aR), preventing the recruitment and activation of inflammatory cells in ocular tissues. By inhibiting this key step in the complement cascade, the drug reduces inflammatory cytokine production and tissue damage in the eye. This mechanism is particularly relevant for dry eye disease and other ocular surface inflammatory conditions.","oneSentence":"HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:43.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT04633213","phase":"PHASE3","title":"A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye","status":"UNKNOWN","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-02-24","conditions":"Dry Eye","enrollment":674},{"nctId":"NCT04092907","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2019-03-22","conditions":"Dry Eye","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HBM9036 0.25% Ophthalmic Solution","genericName":"HBM9036 0.25% Ophthalmic Solution","companyName":"Harbour BioMed (Guangzhou) Co. Ltd.","companyId":"harbour-biomed-guangzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye. Used for Dry eye disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}